<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) has been shown, in many instances, to protect B cells from <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via expression of select EBV proteins and up-regulation of bcl-2 or its homologues </plain></SENT>
<SENT sid="1" pm="."><plain>However, at present little is known about the influence of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Many anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatments act via inhibition of protein synthesis and so could influence the reported protein-dependent mechanisms involved in EBV inhibition of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (BJA-B) cells were treated with a potent <z:chebi fb="0" ids="48001">protein synthesis inhibitor</z:chebi>, <z:chebi fb="0" ids="27641">cycloheximide</z:chebi> (CHX) </plain></SENT>
<SENT sid="4" pm="."><plain>Two variants of BJA-B cells were used, one with <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> (EBV(+)), and one free of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (EBV(-)) </plain></SENT>
<SENT sid="5" pm="."><plain>Cells were collected 0,3,6,12, 24 and 48 h after addition of either 1 or 50 micrograms/mL of CHX </plain></SENT>
<SENT sid="6" pm="."><plain>Control cultures were untreated </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was quantified using established morphological and biochemical characteristics, and protein concentrations assessed </plain></SENT>
<SENT sid="8" pm="."><plain>CHX treatment of EBV(-) BJA-B cells induced massive levels of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was inhibited, but remained significantly higher than that found in control cultures, in similarly treated EBV(+) cells </plain></SENT>
<SENT sid="10" pm="."><plain>The study demonstrates that induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV(-) and EBV(+) cells is not dependent on new protein synthesis and so may be indicative of a bcl-2 independent mechanism in this instance </plain></SENT>
<SENT sid="11" pm="."><plain>The results have important implications for devising and assessing treatment of EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>